Development of a Genetic Test Indicating Increased AVP/V1b Signalling in Patients with Acute Depression

Abstract

Introduction

A subgroup of patients with acute depression show an impaired regulation of the hypothalamic-pituitary-adrenocortical axis, which can be sensitively diagnosed with the combined dexamethasone (dex)/corticotropin releasing hormone (CRH)–test. This neuropathological alteration is assumed to be a result of hyperactive AVP/V1b signalling. Given the complicated procedure of the dex/CRH-test, this study aimed to develop a genetic variants-based alternative approach to predict the outcome of the dex/CRH-test in acute depression.

Methods

Using data of a representative cohort of 352 patients with severe depression participating in the dex/CRH-test, a genome-wide interaction analysis was performed starting with an anchor single nucleotide polymorphism located in the upstream transcriptional region of the human V1b-receptor gene to predict the adrenocorticotropic hormone (ACTH) response to this test. A probabilistic neural-network-algorithm was used to develop the optimal prediction model.

Results

Overall prediction accuracy for correctly identifying high ACTH responders in the dex/CRH-test was 93.5% (sensitivity 90%; specificity 95%). Analysis of pituitary RNAseq expression data confirmed that the identified genetic interactions of the gene test translate into an interactive network of corresponding transcripts in the pituitary gland, which is the biologically relevant target tissue, with the aggregated strength of the transcript interactions significantly stronger than expected from chance.

Discussion

The findings suggest the suitability of the presented gene test as a proxy for hyperactive AVP/V1b signalling during an acute depressive episode, highlighting its potential as companion test for identifying patients with acute depression whose pathology can be optimally treated by specific drugs targeting the AVP/V1b-signaling cascade.

Keywords

depression - dex/CRH-test - arginine-vasopressin - companion test

Publikationsverlauf

Eingereicht: 21. Oktober 2024

Angenommen nach Revision: 10. Dezember 2024

Artikel online veröffentlicht:
29. Januar 2025

• References

• 1 Roser M. Mental illnesses prevalence, World, 2021. Our World in Data. United Kingdom: Global Change Data Lab; 2024
• 2 Heim C, Newport DJ, Mletzko T. et al. The link between childhood trauma and depression: Insights from HPA axis studies in humans. Psychoneuroendocrinology 2008; 33: 693-710
• 3 Monroe SM, Anderson SF, Harkness KL. Life stress and major depression: The mysteries of recurrences. Psychol Rev 2019; 126: 791-816
• 4 Phillips AC, Carroll D, Der G. Negative life events and symptoms of depression and anxiety: Stress causation and/or stress generation. Anxiety Stress Coping 2015; 28: 357-371
• 5 Heim C, Nemeroff CB. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry 1999; 46: 1509-1522
• 6 de Kloet ER, Joels M, Holsboer F. Stress and the brain: From adaptation to disease. Nat Rev Neurosci 2005; 6: 463-475
• 7 Holsboer F, Ising M. Stress hormone regulation: Biological role and translation into therapy. Annu Rev Psychol 2010; 61: 81-109
• 8 Holsboer F, Ising M. Hypothalamic stress systems in mood disorders. Handb Clin Neurol 2021; 182: 33-48
• 9 Heuser IJ, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 1994; 28: 341-356
• 10 Ising M, Kunzel HE, Binder EB. et al. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1085-1093
• 11 von Bardeleben U, Holsboer F, Stalla GK. et al. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sciences 1985; 37: 1613-1618
• 12 Hatzinger M, Wotjak CT, Naruo T. et al. Endogenous vasopressin contributes to hypothalamic-pituitary-adrenocortical alterations in aged rats. J Endocrinol 2000; 164: 197-205
• 13 Keck ME, Wigger A, Welt T. et al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: Implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002; 26: 94-105
• 14 Holsboer F, Ising M. Precision psychiatry approach to treat depression and anxiety targeting the stress hormone system – V1b-antagonists as a case in point. Pharmacopsychiatry 2024;
• 15 Landgraf R. The involvement of the vasopressin system in stress-related disorders. CNS Neurol Disord Drug Targets 2006; 5: 167-179
• 16 Griebel G, Simiand J, Serradeil-Le Gal C. et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 2002; 99: 6370-6375
• 17 Landgraf R, Wigger A. High vs low anxiety-related behavior rats: An animal model of extremes in trait anxiety. Behav Genet 2002; 32: 301-314
• 18 Landgraf R, Gerstberger R, Montkowski A. et al. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995; 15: 4250-4258
• 19 Meynen G, Unmehopa UA, van Heerikhuize JJ. et al. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biol Psychiatry 2006; 60: 892-895
• 20 Purba JS, Hoogendijk WJ, Hofman MA. et al. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996; 53: 137-143
• 21 Zhou JN, Riemersma RF, Unmehopa UA. et al. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001; 58: 655-662
• 22 Modell S, Lauer CJ, Schreiber W. et al. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology 1998; 18: 253-262
• 23 Ising M, Horstmann S, Kloiber S. et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker?. Biol Psychiatry 2007; 62: 47-54
• 24 Zobel AW, Yassouridis A, Frieboes RM. et al. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 1999; 156: 949-951
• 25 Dempster EL, Burcescu I, Wigg K. et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psychiatry 2007; 64: 1189-1195
• 26 van West D, Del-Favero J, Aulchenko Y. et al. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry 2004; 9: 287-292
• 27 Hennings JM, Owashi T, Binder EB. et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – Findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 2009; 43: 215-229
• 28 Zobel AW, Nickel T, Sonntag A. et al. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J Psychiatr Res 2001; 35: 83-94
• 29 GTEx-Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 2020; 369: 1318-1330
• 30 Kearns NP, Cruickshank CA, McGuigan KJ. et al. A comparison of depression rating scales. Br J Psychiatry 1982; 141: 45-49
• 31 Zimmerman M, Martinez JH, Young D. et al. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 2013; 150: 384-388
• 32 Harrow J, Frankish A, Gonzalez JM. et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 2012; 22: 1760-1774
• 33 Schüle C, Baghai T, Zwanzger P. et al. Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology (Berl) 2003; 166: 271-275
• 34 Sarubin N, Nothdurfter C, Schmotz C. et al. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. Psychoneuroendocrinology 2014; 39: 141-151
• 35 Kunzel HE, Binder EB, Nickel T. et al. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 2003; 28: 2169-2178
• 36 Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: The end of the beginning?. Nat Rev Drug Discov 2012; 11: 462-478